KAINOS Laboratories, Inc.

4556

JP3205650009

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-21 EDT			5-day change	1st Jan Change
1,153 ^JPY	-0.52%		+0.70%	+5.68%

2022	KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation	CI
2022	KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation	CI

Kainos Laboratories, Inc. authorizes a Buyback Plan.

August 24, 2015

The Board of Directors of Kainos Laboratories, Inc. has authorized a buyback plan on August 25, 2015.

Latest news about KAINOS Laboratories, Inc.

KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation	22-03-13	CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation	22-02-24	CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.	21-11-25	CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.	21-11-25	CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.	21-11-25	CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.	21-11-24	CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.	20-11-25	CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2020, has closed with 88,000 shares, representing 2.02% for ¥90.29 million.	20-11-25	CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 90,000 shares, representing 2.02% for ¥100 million.	20-11-25	CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.	20-11-24	CI
KAINOS Laboratories, Inc. announced that it has received ¥435.12 million in funding from Asahi Kasei Pharma Corporation	19-05-28	CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥435.12 million in funding from Asahi Kasei Pharma Corporation	19-05-12	CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on September 25, 2018.	18-09-25	CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on September 25, 2018 has expired with 490,800 shares, representing 11.01% for ¥541.35 million. The company repurchased 490,800 shares from Hitachi Chemical Company, Ltd..	18-09-25	CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 500,000 shares, representing 11.22% for ¥551.5 million.	18-09-25	CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.	18-09-24	CI
Kainos Laboratories, Inc. announced that it has received ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm.	16-02-09	CI
Kainos Laboratories, Inc. announced that it expects to receive ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm.	16-01-24	CI
Tranche Update on Kainos Laboratories, Inc.'s Equity Buyback Plan announced on August 25, 2015.	15-08-25	CI
Kainos Laboratories, Inc.'s Equity Buyback announced on August 25, 2015, has expired with repurchase of 270,000 shares, representing 6.07% for ¥160.65 million.	15-08-25	CI
Kainos Laboratories, Inc. announces an Equity Buyback for 300,000 shares, representing 6.74% for ¥210 million.	15-08-25	CI
Kainos Laboratories, Inc. authorizes a Buyback Plan.	15-08-24	CI

Chart KAINOS Laboratories, Inc.

Duration

Period

More charts

KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-21 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
KAINOS LABORATORIES, INC.	+5.68%	33.04M
BIOMÉRIEUX	-6.26%	12.23B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.93%	8.17B
DIASORIN S.P.A.	+7.10%	5.78B
LANTHEUS HOLDINGS, INC.	+30.98%	5.74B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.47%	4.24B
10X GENOMICS, INC.	-56.42%	2.97B
ANDON HEALTH CO., LTD.	+12.56%	2.73B
VITROLIFE AB	-4.67%	2.38B
MYRIAD GENETICS, INC.	+27.95%	2.26B

Diagnostic & Testing Substances